• Member News

PhoreMost appoints Dr Lorenz Mayr as Non-Executive Director

Board appointment will help guide target identification and drug discovery

Dr. Philip Beer joins CCG.ai

Dr. Philip Beer joins Cambridge Cancer Genomics as Head of Translational Medicine

Invest Newcastle show off the region’s innovative life science sector to Cuban visitors

Invest Newcastle has welcomed a senior Cuban life science business delegation to the region for a two-day visit. They used this opportunity to show off the city’s life science strengths and world-leading universities.

Arecor Signs A New Formulation Evaluation Agreement With An Existing Partner, A Major Global Pharmaceutical Company

Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company.

PhoreMost and inStem enter structural biology alliance

inStem’s Centre for Chemical Biology and Therapeutics to work with PhoreMost to progress selected targets

Global Head of Neuroscience Discovery marks the official launch of The Biosphere

On Thursday 4 July Dr. Fiona Marshall, Global Head of Neuroscience Discovery, MSD visited Newcastle to mark the official launch of The Biosphere.

Horizon Discovery’s SMARTvector shRNA technology deployed in Celyad’s successful IND filing for next-generation CAR-T cell therapy, CYAD-02

• Phase 1 trial scheduled for early 2020 will be first CAR-T cell therapy clinical trial to employ SMARTvector technology • Horizon will receive a milestone payment for the successful IND filing of CYAD-02, autologous NKG2D-based CAR-T candidate

The healthcare industry: primed to profit from AI and machine learning

Artificial Intelligence (AI) and machine learning in healthcare and life sciences holds the promise of reforming the industry. Generating and harnessing mass pools of data, the healthcare and life science industries are particularly primed to profit from the potential of AI, offering the unearthing of hidden insights in a world of unstructured data. Frost and Sullivan predicts that the health AI market, valued at US$600 million in 2014 will reach a high of US$6.2 billion by 2022.

Cancer vaccine firm Oxford Vacmedix announces collaboration and Innovate UK grant

CHAIN Biotechnology and University of Oxford have been awarded grant funding to develop live biotherapeutics that support oral delivery of Oxford Vacmedix’s immunotherapy cancer vaccines.

Theolytics Limited comes out of stealth mode with Dr Ken Powell announced as Chair of the Board

We're thrilled to announce the appointment of Dr Ken Powell as Chair to the Board of Directors for Theolytics. Ken brings extensive virology and commercial expertise, including from founding roles at Arrow Therapeutics and Reviral.